RCUS GuruFocus.com 2 days ago Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Report Preview: What to Look For ➖ AI Sentiment Neutral 4/10
RCUS Business Wire 3 days ago Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer